Phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group (WJTOG) study

@article{Takeda2007PhaseIS,
  title={Phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group (WJTOG) study},
  author={Koji Takeda and Nobuhide Takifuji and Shunichi Negoro and Kiyoyuki Furuse and Shinichiro Nakamura and Yoshiki Takada and Takanobu Hoso and Shinichi Hayasaka and Takashi Nakano and Jun Araki and Hiroshi Senba and Fumiyuki Iwami and Yasufumi Yamaji and Masahiro Fukuoka and Harumichi Ikegami},
  journal={Investigational New Drugs},
  year={2007},
  volume={25},
  pages={377-383}
}
Purpose: We conducted a multicenter phase II study of amrubicin, a novel 9-aminoanthracycline, to evaluate its efficacy and safety in patients with non-small-cell lung cancer (NSCLC). Patients and methods: Entry requirements included cytologically or histologically proven measurable NSCLC, stage III or IV, no prior therapy, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2, and adequate organ function. Amrubicin was given by daily intravenous injection at 45 mg/m2/day… CONTINUE READING
11 Citations
20 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 20 references

Similar Papers

Loading similar papers…